Cara Therapeutics | Sustainability Performance
Develops pharmaceutical treatments focused on addressing pain management and related conditions.
2004
United States
51 - 200 employees
Biotechnology
$10M - 25M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#10846
Overall#2429
in United States#226
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Environmental
Digital emissionsGovernance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Digital Emissions
CO2e per visit (g)
Industry benchmark
B/M 0.26 g
Green HostingYes
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$7.0MFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
-%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-86.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.0
▼ 28.5%
0.0
▲ 43.0%
0.0
2030Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Available
Recycling policy
Not available
Workplace health & safety policy
Available
45%
Independent Directors
5 out of 11 incl. management
Overall score
56
Environment
53
Social
99
Governance
16
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
